Androgen Deprivation Therapy May Increase Risk for Heart Failure, Study Says

Androgen Deprivation Therapy May Increase Risk for Heart Failure, Study Says
Men with localized prostate cancer who received androgen deprivation therapy may be at greater risk of heart failure than those who did not receive the treatment, a new study suggests. The study, “Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study,” was published in the British Journal of Cancer. Androgen deprivation therapy (ADT) is a type of therapy that reduces the levels of male hormones – androgens – to prevent them from promoting the growth of prostate cancer cells. It has been used widely for patients with advanced prostate cancer. More recently, it is being used increasingly to treat patients in the early stages of the disease, before it has spread. While some studies with elder patients suggest that ADT may increase the risk for cardiovascular disease, there is still conflicting evidence regarding the association between ADT and cardiovascular problems. Using records from Kaiser Permanente Southern California (KPSC) healthcare delivery system, authors underwent a prospective study with men newly diagnosed with localized prostate cancer, who initially were under active surveillance. This is a monitoring strategy to ensure the cancer hasn't spread outside the prostate. Studying records from 7,637 subjects, they looked at how ADT affected patients’ risk for cardiovascular disease. Nearly 30 percent were exposed to ADT and patients were followed for up to 12 years after diagnosis. The analysis sh
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *